



14th May 2025

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500674

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra East,
Mumbai 400 050
Symbol: SANOFI

Sub: Outcome of the Board Meeting of the Company held on Wednesday, 14th May 2025

Dear Sirs/Madam,

We refer to our letter dated 9th May 2025 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Wednesday, 14th May 2025, *inter-alia* considered and approved the Unaudited Financial Statements for the Quarter ended 31st March 2025.

Accordingly, we enclose a copy of the Limited Review Report, and the Unaudited Financial Statements for the Quarter ended 31st March 2025 as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information. A press release in this regard has also been enclosed.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid financial results will also be available on the Company's website on [Financial results - Sanofi India](#)

The meeting of Board of Directors commenced at 2:30 p.m. and concluded at 4:40 p.m.

Please take the above information on record.

Thanking you,

Yours faithfully
For **Sanofi India Limited**

Arjun Thakkar
Company Secretary and Compliance Officer
Membership No.: A22654

Sanofi India Limited declares 4% growth in net sales & 27% growth in operating profits in Q1-2025

Standalone Profit from Operations for the quarter were INR 162 crores

Mumbai, May 14, 2025. Sanofi India Limited (SIL) today declared its financial results for the quarter ended on March 31st, 2025. The Company has delivered net sales growth of 4% on a comparable basis of continuing business.

The successful launch of Soliqua®, our best-in-class diabetes drug for the premix segment, continues with a steady growth reinstating confidence and strength in our comprehensive diabetes portfolio.

The Company was able to increase its operating profit (*) in Q1-2025 by 27% vs Q1-2024. The improved operating profit was a result of the Company's focus mainly on lowering expenses through overall operating efficiencies.

The Company continues to make good progress on its 'India for India' strategy through go-to-market initiatives, improving operating efficiency and promoting innovation.

()*: Operating profit = Revenue from operations – Total expenses

Rachid Ayari

Whole Time Director and Chief Financial Officer

"The Company has delivered a strong first quarter performance reflecting Sanofi's successful strategy for India. The Company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its best-in-class innovative products in India."

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 60+ other countries. Sanofi has located one of its four global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices since 2019, Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: www.sanofi.com/en/in, [LinkedIn](#) and [Twitter](#).

Media Relations

Vinifer Gandhi | vinifer.gandhi@sanofi.com

Price Waterhouse & Co Chartered Accountants LLP

Review Report

To
The Board of Directors
Sanofi India Limited
CTS No. 117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai 400 072

1. We have reviewed the unaudited financial results of Sanofi India Limited (the "Company") for the quarter ended March 31, 2025, which are included in the accompanying 'Statement of Unaudited Financial Results for the quarter ended March 31, 2025' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been digitally signed by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009

Place: Mumbai	Arunkumar Ramdas
Date: May 14, 2025	Partner
	Membership Number: 112433
	UDIN: 25112433BMOUXU7831

Price Waterhouse & Co Chartered Accountants LLP, Nesco IT Building III, 8th Floor, Nesco IT Park, Nesco Complex
Gate No. 3 Western Express Highway, Goregaon East, Mumbai – 400 063
T: +91 (22) 61197808

Registered office and Head office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

SANOFI INDIA LIMITED

Registered Office : Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.
Corporate Identity Number: L24239MH1956PLC009794
Tel no: (91-22) 28032000 Fax No: (91-22) 28032846
Website: www.sanofiindia.com Email: igrc.sil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025

Particulars	₹ in Million			
	Quarter ended	Quarter ended	Quarter ended	Year ended
	31.03.2025 (Unaudited)	31.12.2024 (Unaudited) (Refer Note 3 and 5)	31.03.2024 (Unaudited) (Refer Note 3)	31.12.2024 (Audited) (Refer Note 3)
Continuing Operations				
1. Revenue from Operations	5,359	5,149	5,108	20,132
2. Other Income	33	59	35	165
3. Total Income (1+2)	5,392	5,208	5,143	20,297
4. Expenses				
(a) Cost of Materials Consumed	757	1,027	769	3,548
(b) Purchases of stock in trade	841	2,385	315	5,643
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	807	(914)	1,400	602
(d) Employee benefits expense	538	538	695	2,402
(e) Finance costs	3	4	3	15
(f) Depreciation and amortisation expense	96	96	91	367
(g) Other expenses	697	930	558	3,029
Total Expenses	3,739	4,066	3,831	15,606
5. Profit before exceptional items and tax from continuing operations (3-4)	1,653	1,142	1,312	4,691
6. Exceptional items (Refer note 4)	-	80	(267)	(377)
7. Profit before tax from continuing operations (5+6)	1,653	1,222	1,045	4,314
8. Tax expense from continuing operations				
Current Tax	457	279	397	1,258
Deferred Tax	1	30	(72)	(81)
9. Profit for the period /year from continuing operations (7-8)	1,195	913	720	3,137
10. Profit before tax from discontinued operations	-	-	839	1,312
11. Tax expense from discontinued operations	-	-	193	314
12. Profit for the period /year from discontinued operations (10-11)	-	-	646	998
13. Profit for the period /year (9+12)	1,195	913	1,366	4,135
14. Other comprehensive income (OCI) (Net of Tax) from continuing operations	-	72	-	72
15. Other comprehensive income (OCI) (Net of Tax) from discontinued operations	-	-	-	-
16. Total Other comprehensive income (OCI) (Net of Tax) (14+15)	-	72	-	72
17. Total comprehensive income for the period/year (13+16)	1,195	985	1,366	4,207
18. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230
19. Other equity	-	-	-	8,376
20. Basic and diluted earnings per share (not annualised) (in ₹)				
Continuing Operations	51.89	39.64	31.26	136.21
Discontinued Operations	-	-	28.05	43.33
Continuing and Discontinued Operations	51.89	39.64	59.31	179.54

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the audit report dated May 14, 2025

Notes:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 14, 2025. The statutory auditors have carried out a limited review of the above results for the quarter ended March 31, 2025.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. The Company demerged its Consumer Healthcare business effective June 1, 2024 after obtaining approval of the NCLT. Consequently, financial results for the Consumer Healthcare business are presented as discontinued operations for periods ending March 31, 2024, and December 31, 2024.
4. Exceptional item for the quarter ended March 31, 2024, includes personnel separation cost amounting to ₹ 267 million. For the year ended December 31, 2024, exceptional cost relates to personnel separation cost amounting to ₹377 million net of a reversal of ₹80 million in the quarter ended December 31, 2024.
5. The figures for the quarter ended December 31, 2024 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2024 and the unaudited published year-to-date figures up to September 30, 2024 which was subject to limited review, being the date of the end of the third quarter of the said financial year.
6. The Company has a single business segment namely 'Pharmaceutical Business'.

SANOFI INDIA LIMITED

The statutory auditors have digitally
signed this statement for identification
purposes only and this Statement should
be read in conjunction with the review report
dated May 14, 2025

May 14, 2025

RACHID AYARI
WHOLETIME DIRECTOR & CFO
DIN: 10408699